Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities
-
Published:2023-03-08
Issue:6
Volume:24
Page:5205
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Yang Pingping1ORCID, Ren Jun23ORCID, Yang Lifang14ORCID
Affiliation:
1. Department of Anesthesiology, Xi’an Children Hospital, Xi’an 710032, China 2. Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 200032, China 3. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA 4. Key Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, Xi’an 710003, China
Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although a cadre of therapeutic strategies have been made available for CVDs in the clinical setting, predominantly through medication and surgery, these do not fully address the clinical needs of patients with CVD. As a new technique for CVD treatment, nanocarriers are employed to modify and package medications to ease the targeting of tissues, cells and molecules within the cardiovascular system. Nanocarriers are made of biomaterials, metals, or a combination of these materials, with sizes similar to bioactive molecules such as proteins and DNA. Cardiovascular nanomedicine (CVN) has only surfaced in recent years and is still in its infancy. Ample studies have displayed promise for the clinical utility of nanomedicine techniques, courtesy of continued perfection in nanocarrier design to optimize drug delivery and treatment outcomes. Here in this review, we will summarize the research advances in the literature on nanoparticles in the management of CVDs, including ischemic and coronary heart disease (e.g., atherosclerosis, angina pectoris and myocardial infarction), myocardial ischemia-reperfusion injury, aortic aneurysm, myocarditis, hypertension, and pulmonary artery hypertension and thrombosis.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference93 articles.
1. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association;Tsao;Circulation,2022 2. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study;Roth;J. Am. Coll. Cardiol.,2020 3. Zhu, C., Ma, J., Ji, Z., Shen, J., and Wang, Q. (2021). Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders. Molecules, 26. 4. Obesity Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications;Ren;Physiol. Rev.,2021 5. Manners, N., Priya, V., Mehata, A.K., Rawat, M., Mohan, S., Makeen, H.A., Albratty, M., Albarrati, A., Meraya, A.M., and Muthu, M.S. (2022). Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives. Pharmaceuticals, 15.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|